Clinical trials: Anxiety
Depressive Disorder, Major, Anxiety Disorders
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and…
- Trial name
- BASIS (NCT04770454)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis.
- Conditions
- Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia
- Trial name
- NCT07072728
- Testing
- Psilocybin therapy
- Where
- 5 sites in Australia
- Volunteers
- 87 people
- Sponsor
- Psyence Australia Pty Ltd
Major Depressive Disorder With Anxious Distress
A Study of JNJ-61393215 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a 17-item Hamilton Depression Rating Scale…
- Trial name
- NCT04080752
- Testing
- JNJ-61393215
- Where
- 35 sites in United States, Moldova and 3 more
- Volunteers
- 222 people
- Sponsor
- Janssen Research & Development, LLC
Dental Anxiety, Dental Pain
Nonpharmacologic Reduction of Periprocedural Pain and Anxiety in Dentistry
Dental pain and anxiety are usually managed by local anesthetics and sedatives, but patient anxiety and fear of pain remain common and adversely affect oral health behavior and outcomes.
- Conditions
- Dental Anxiety, Dental Pain, Root Work
- Trial name
- NCT05194449
- Testing
- Comfort Talk® App
- Sponsor
- Hypnalgesics, LLC
Autism Spectrum Disorder (ASD)
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)
The purpose of this study is to establish the potential benefits, safety, and tolerability of AB-2004 in participants with irritability associated with autism spectrum disorder.
- Trial name
- NCT04895215
- Testing
- AB-2004
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 156 people
- Sponsor
- Vertero Therapeutics
Obsessive Compulsive Disorder
Tolerability, Safety and Efficacy of the HAC-Coil Deep Transcranial Magnetic Stimulation in Medication Resistance Obsessive Compulsive Disorder (OCD) Subjects
The purpose of this study is to test whether the combination of deep transcranial magnetic stimulation (DTMS) treatment with customary medication for obsessive compulsive disorder (OCD) patients is effective than treatment that…
- Trial name
- NCT01343732
- Testing
- Deep TMS
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Brainsway
Generalized Anxiety Disorder
A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
This study will evaluate the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder.
- Trial name
- NCT00542685
- Testing
- PD 0332334
- Where
- 43 sites in United States
- Volunteers
- 551 people
- Sponsor
- Pfizer
Panic Disorder
Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)
The purpose of this study is to evaluate the effectiveness of Org 25935 vs. placebo given in combination with cognitive-behavioral therapy (CBT) to reduce the symptoms of panic disorder.
- Trial name
- NCT00725725
- Testing
- Cognitive-behavioral therapy, Org 25935
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without…
- Trial name
- NCT07065240
- Testing
- SPT-300
- Where
- 61 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Anxiety, Stress
Radicle Calm 2: A Study of Health and Wellness Products on Feelings of Anxiety, Stress, and Health Outcomes
A randomized, double-blinded, placebo-controlled study assessing the impact of health and wellness products on feeling of anxiety, stress, and other health outcomes
- Trial name
- NCT05837910
- Testing
- Calm Active Study Product 1.1 Usage, Calm Active Study Product 1.2 Usage, Calm Active Study Product 1.3 Usage
- Where
- United States
- Volunteers
- 3,853 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Depressive Disorder and Anxiety Disorders
First Study in Humans With GSK424887
This is the first study in Humans with GSK424887 to evaluate what effects, good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body…
- Trial name
- NCT01059591
- Testing
- GSK424887, PET
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Generalized Anxiety Disorder
Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder
The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
- Trial name
- NCT00481325
- Testing
- pexacerfont, escitalopram
- Where
- 51 sites in United States
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Anxiety
Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280
The study is carried out in order to determine the relationship between the dose of AZD6280 and the blood concentration of AZD6280, and to investigate to which extent AZD6280 binds to GABAA receptors
- Trial name
- PET (NCT00681746)
- Testing
- AZD6280, (11C) flumazenil
- Where
- Sweden
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Anxiety Disorders, Major Depressive Disorder
Acquisition and Analysis of Relationships Between Longitudinal Emotional Signals Produced by an Artificial Intelligence Algorithm and Self-questionnaires Used in the Psychiatric Follow-up of Patients With Mood and/or Anxiety Disorders: a Real-Environment Study.
The worldwide prevalence of anxiety and depression increased massively during the pandemic, with a 25% rise in the number of patients suffering from psychological distress.
- Trial name
- EMOACQ-1 (NCT05988840)
- Testing
- Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emobot
Sleep Troubles Associated With Anxiety
Evaluation of a Combination of Plants in Anxiety-related Sleep Disorders: Randomized Trial Versus Placebo
The objective of this double-blind randomized clinical trial is to compare the effects of a dietary supplement based on eschscholtzia and valerian extracts to a placebo after 28 days of supplementation, in subjects suffering from…
- Trial name
- NCT04812418
- Testing
- Noctesia
- Where
- Belgium
- Volunteers
- 109 people
- Sponsor
- PiLeJe
Healthy Controls
Identification of a Safe and Non-Psychedelic Dose of Psilocybin
This randomized, double-blind, placebo-controlled, single ascending dose study will evaluate psilocybin in healthy adult subjects.
- Trial name
- NCT07710027
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Diamond Therapeutics Inc.
Depressive Disorder and Anxiety Disorders
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
The study will consist of a screening period, 3 treatment periods and a post-treatment follow-up. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a…
- Trial name
- NCT00536679
- Testing
- GSK163090 capsule, fasted, GSK163090 Tablet, fasted, GSK163090 Tablet, fed
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00417118
- Testing
- Saredutant, Escitalopram
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 365 people
- Sponsor
- Sanofi
Depression, Anxiety
Feasibility and Acceptability of W-GenZD vs CBT-light Teletherapy for Adolescents Seeking Mental Health Services
The primary aim of this study is to determine the feasibility and acceptability of the W-GenZD mobile application among a group of adolescents and who have screened and triaged into low-intensity treatment within the Children's…
- Trial name
- NCT05372913
- Testing
- Woebot for Adolescents (W-GenZD) Mobile Application, CBT-Lite Teletherapy Group
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Woebot Health
General Anxiety Disorder
A Dose-Response Safety Study of ENX-102 in Patients With GAD
This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD
- Trial name
- NCT06653296
- Testing
- ENX-102
- Where
- 3 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Engrail Therapeutics INC